FDA Grants IND Approval for HC016 Lipid Complex Injection, a First-in-Class LNP-Delivered TLR9 Agonist Developed by Haichang Biopharma

HC016 US IND Approved

New Year's Eve, also known as the Chinese Lunar New Year's Eve, is a traditional Chinese festival. It falls on the last night of the 12th month of the lunar calendar, marking the end of the old year.

On January 18, 2025, HC016 Lipid Complex Injection (hereinafter referred to as “HC016”), a novel small nucleic acid drug independently developed by Haichang Biotech, successfully obtained clinical trial approval from the U.S. Food and Drug Administration (FDA).HC016 Based on Haichang Biotech QTsome^TMA technology platform with a novel Toll-like receptor 9 (TLR9) agonist as the active ingredient, aimed at providing effective clinical treatment options for various solid tumors such as melanoma, head and neck cancer, and osteosarcoma.

      As the world's first immune agonist using lipid nanoparticle (LNP) delivery technology, HC016 has demonstrated significant therapeutic advantages in preclinical studies, including notable tumor regression, metastasis suppression, and recurrence inhibition.

     With the advent of immune checkpoint inhibitors, cancer immunotherapy has been highly anticipated. Treatment methods based on immune agonists such as TLR9 have shown excellent therapeutic effects in clinical studies but have failed to become viable drugs due to safety concerns. In contrast, HC016, an innovative TLR9 agonist from Haichang Biotech, demonstrates better activation effects on core components of anti-tumor immunity, including T cells, macrophages, and NK cells. Circulating memory-type immune cells can effectively monitor and kill distant metastases and circulating tumor cells. Preclinical data shows that QTsome...^TMThe delivery system enables the drug to effectively accumulate at the tumor site with almost no significant upregulation of cytokines in the blood, addressing the safety issues that traditional TLR9 agonists have struggled to overcome. Meanwhile, TLR9 is an intracellular receptor, and QTsome...^TMThe efficient cellular uptake and endosomal release provided significantly reduce the effective dosage. Notably, tumor cells often metastasize through the lymphatic system, and studies have confirmed that QTsome...^TMThe encapsulated drug can partially enter the tumor-draining lymph nodes, track and kill tumor cells, and exert a distant surveillance effect.

Traditional tumor therapeutic drugs commonly face issues of drug resistance, with low five-year survival rates and significant side effects. Even newer immune checkpoint inhibitors have shown poor response in some patients, with approximately 40%-60% of patients failing to benefit significantly from such treatments. Immunotherapy represents the most promising direction for solid tumor research and development. HC016’s comprehensive improvement of the tumor immune microenvironment will substantially enhance the responsiveness to immune checkpoint inhibitors, TKI inhibitors, and other drugs, offering broad application prospects. Meanwhile, HC016 has already demonstrated significant therapeutic effects on more than five types of solid tumors in preclinical studies and is expected to be developed into a "pan-tumor drug" with wide applicability, bringing hope to more patients.

Haichang Biotech will continue to uphold the spirit of innovation, fully accelerate the clinical development process of HC016, and actively seek cooperation with more strategic partners, jointly committing to bringing this groundbreaking drug to the market as soon as possible, offering new treatment hope for cancer patients worldwide.

About Haichang Biotech